力生制药：阿普米司特片通过上市许可申请

Core Viewpoint - Company Tianjin Central Pharmaceutical Co., Ltd., a subsidiary of Lisheng Pharmaceutical, has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in 10mg, 20mg, and 30mg specifications, indicating successful approval for market access [1] Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1]